Gruppo Oncologico del Nord-Ovest

New phase 2 trial NCT06578559 posted by Gruppo Oncologico del Nord-Ovest: "Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 246 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 2 trial NCT05845450 posted by Gruppo Oncologico del Nord-Ovest: "Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)". New trial on a phase 2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 180 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.